Login to Your Account

Other News To Note

Friday, December 28, 2012
• Auxilium Pharmaceuticals Inc., of Malvern, Pa., said its supplemental Biologics License Application for Xiaflex (collagenase clostridium histolyticum), a therapy for the potential treatment of Peyronie's disease (PD) has been accepted for filing and granted standard review status by the FDA.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription